Seer Q3 revenue $4.2M (+5% YoY), net loss $21.1M; guides to lower half of FY range

Seer, Inc.

2023-Q3 EPS reported -$1.07 revenue$12,223,000

Revenue $4.2M (+5% YoY); product revenue $3.3M incl $1.4M related party; service $536K; grant $348K.
Net loss $21.1M vs $24.0M YoY; operating expenses $28.0M with $8.3M stock-based compensation.
Cash and investments $380.8M at Sep 30, 2023.
FY 2023 revenue guided to lower half of $16-18M range due to ongoing macroeconomic headwinds.
Expanded geographically with Danyel Biotech (Israel) and GeneTiCA (Eastern Europe); added Panome Bio as Center of Excellence.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Seer, Inc. reported third quarter ended September 30, 2023 results: revenue $4.2 million, net income $21.1 million. Guidance lowered.

Period: third quarter ended September 30, 2023
Revenue: $4.2 million
Net income: $21.1 million
Guidance: lowered
Result: reported results

Exact text from the filing

a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights • Achieved revenue of $4.2 million for the third quarter of 2023, an increase of 5% over the prior year period • Expanded geographically with two new partners - Danyel Biotech in Israel and GeneTiCA in Eastern

View on SEC.gov

Browse all earnings releases →

Seer, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.